Innoviva Inc

Research Innoviva Inc (INVA) on Bullrun: valuation model: 235.3% undervalued, market cap USD 1.71B, P/E 3.8. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerINVA
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Valuation signal235.3% undervalued
• Market capUSD 1.71B
• P/E3.8
• Financial periodFY2025
• RevenueUSD 411.33M
• Revenue growth14.7%
• Net incomeUSD 271.17M
• Free cash flowUSD 195.80M
• Gross margin74.8%

Valuation Snapshot

Bullrun's latest valuation model marks Innoviva Inc as 235.3% undervalued; latest market cap is USD 1.71B; P/E is 3.8.

About Innoviva Inc

Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The company also markets GIAPREZA for increasing blood pressure in adults with septic or other distributive shock;

Frequently asked questions

Is Innoviva Inc overvalued or undervalued?

Bullrun's valuation model currently marks Innoviva Inc as 235.3% undervalued.

What is Innoviva Inc's market cap?

Innoviva Inc's market capitalization is USD 1.71B.

What is Innoviva Inc's P/E ratio?

Innoviva Inc's price-to-earnings (P/E) ratio is 3.8.

What does Innoviva Inc do?

Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate;